Adis Summary of Research: Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents
AbstractCoronavirus disease 2019 (COVID-19) has a high mortality rate among the elderly, particularly among frailer and older individuals living in long-term care facilities (LTCFs). In Spain, a large number of patients in this priority group had received the COVID-19 vaccine, including the mRNA vaccine BNT162B2, by April 2021. This Adis Summary of Research summarizes the effects of the BNT162B2 mRNA vaccine among residents in an LTCF in Spain, based on an observational study. Vaccination in elderly LTCF residents was not linked with an increased safety risk, with no apparent contraindications even in more frail individual...
Source: Drugs and Therapy Perspectives - July 29, 2023 Category: Drugs & Pharmacology Source Type: research
Tapinarof cream 1% in plaque psoriasis: a profile of its use
AbstractTapinarof (VTAMA®) cream 1%, a topical, non-steroidal, aryl hydrocarbon receptor agonist, presents a valuable addition to the therapy options for topical treatment of plaque psoriasis in adults. In the pivotal 12-week, randomized, double-blind, vehicle-controlled, phase 3 PSOARING 1 and PSOARING 2 trials, once-daily ta pinarof cream 1% was shown to be efficacious in reducing the severity of plaque psoriasis. Furthermore, evidence from an open-label extension study shows that continuous and intermittent use of tapinarof cream 1% for up to 1 year has durable on-treatment efficacy with a substantial remittive...
Source: Drugs and Therapy Perspectives - July 27, 2023 Category: Drugs & Pharmacology Source Type: research
Consider comorbidities, concomitant medications and organ function when treating chronic urticaria in older adults
AbstractChronic urticaria in older adults is not well understood and specific guidelines on the diagnosis and treatment of this skin condition in older adults are lacking. Care should be taken in the diagnosis of chronic urticaria in older adults, as they may have different clinical features and relevant differential diagnoses than younger adults. The recommended treatment of chronic urticaria in older adults follows the same guidelines as for the general population. However, the choice of pharmacological treatment in older adults requires special consideration, due to the greater prevalence of comorbidities, concomitant m...
Source: Drugs and Therapy Perspectives - July 27, 2023 Category: Drugs & Pharmacology Source Type: research
Manage early morning ADHD symptoms and functional impairment with treatments that are effective from awakening
AbstractThe early morning routine before school can be a particularly challenging time for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Morning-dosed stimulants often fail to adequately address early morning ADHD symptoms and impaired functioning, due to the delay in their onset of effect, which has a significant impact on the entire family. Clinicians should consider treatments that are effective from awakening, such as methylphenidate delayed release/extended release administered in the evening, methylphenidate transdermal system applied to the skin before awakening, or long-acting non-s...
Source: Drugs and Therapy Perspectives - July 21, 2023 Category: Drugs & Pharmacology Source Type: research
Screen for drug-induced gambling disorder in vulnerable patients receiving dopaminergic drugs
AbstractDopaminergic drugs are associated with an increased risk of gambling disorder. It is crucial that patients who are at risk of- or who have developed a gambling disorder are identified so that preventative interventions and treatment can be provided as patients with gambling disorder do not typically seek help. Modification to the dose or the type of dopaminergic drugs prescribed is recommended in cases of drug-induced gambling disorder alongside standard psychological interventions. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - July 21, 2023 Category: Drugs & Pharmacology Source Type: research
Desidustat in anaemia in patients with chronic kidney disease: a profile of its use
AbstractDesidustat (Oxemia™), a hypoxia-inducible factor prolyl hydroxylase inhibitor, is a promising new oral alternative to injectable erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia in patients with chronic kidney disease (CKD). Desidustat is approved in India for adults with CKD who are either not on dialysis or on dialysis. It is administered orally three times a week and dosage should be individualised based on the haemoglobin response of the patient. In clinical trials in patients with non-dialysis-dependent and dialysis-dependent CKD, desidustat was non-inferior to darbepoetin alfa and epoet...
Source: Drugs and Therapy Perspectives - July 13, 2023 Category: Drugs & Pharmacology Source Type: research
Consider new therapies for the treatment and prevention of Clostridioides difficile infection
AbstractNew therapies to treat and preventClostridioides difficile infections (CDI) are needed. CDI requires antibiotic therapy, but this can disrupt gut microbiomes and increase susceptibility to recurrent CDI (rCDI). The search for narrow spectrum, microbiome-sparing antibiotics that can eliminate CDI has been challenging. However, three agents are approved for the prevention of rCDI, including the monoclonal antibody bezlotoxumab and two human donor stool products (rectally administered REBYOTATM and oral VOWSTTM). (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - July 7, 2023 Category: Drugs & Pharmacology Source Type: research
Dextromethorphan/bupropion in major depressive disorder: a profile of its use
AbstractDextromethorphan/bupropion (AUVELITY®), an oral, fixed-dose combination of dextromethorphan hydrobromide and bupropion hydrochloride, is a useful treatment option for adults with major depressive disorder (MDD). Dextromethorphan is an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist. The antidepressant bupropion (an aminoketone and cytochrome P450 2D6 inhibitor) increases the bioavailability of dextromethorphan. In randomized, double-blind, clinical trials in patients with MDD, dextromethorphan/bupropion demonstrated early, clinically meaningful improvements in depressive ...
Source: Drugs and Therapy Perspectives - July 6, 2023 Category: Drugs & Pharmacology Source Type: research
Age is just a number with ulcerative colitis therapies
AbstractLimited data suggest that older patients with ulcerative colitis (UC) irrespective of late-onset UC or disease diagnosed before the age of 60 years, should largely receive similar corticosteroid-sparing agents to as those prescribed to younger patients. Typically, mesalamine is recommended as a first-line agent for induction or maintenance therapy, with biological treatments recommended for more severe disease. The risk profile for adverse drug events should be taken into consideration when selecting an appropriate therapy, for example, immunosuppressants may exacerbate infection risks. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - July 6, 2023 Category: Drugs & Pharmacology Source Type: research
Oteseconazole in recurrent vulvovaginal candidiasis: a profile of its use
AbstractOteseconazole (Vivjoa®), an orally administered azole antifungal, is a valuable, efficacious, and well tolerated treatment option for reducing the incidence of vulvovaginal candidiasis (VVC) recurrence in females with a history of recurrent VVC (RVVC) who are not of reproductive potential. It is the first drug to be approved in the USA for this indication. In phase 3 clinical trials in patients with RVVC, oteseconazole significantly reduced the incidence of VVC recurrence compared with placebo and continued to prevent VVC recurrence for over 36 weeks after the final dose of the drug. Oteseconazole was non-inferior...
Source: Drugs and Therapy Perspectives - July 1, 2023 Category: Drugs & Pharmacology Source Type: research
Manage androgenetic alopecia in men with established options but emerging therapies show promise
AbstractAndrogenetic alopecia (AGA) is the most common type of hair loss disorder and affects both men and women. It is characterized by the progressive miniaturization of hair follicles in androgenetic areas of the scalp resulting in a decrease in hair density. While the number of options for managing AGA has increased over the years, evidence-based information and guidelines are limited. Treatments range from the approved and off-label use of pharmacological agents [including oral 5 α-reductase inhibitors (e.g. dutasteride) and vasodilators (e.g. topical minoxidil)] to non-pharmacological treatments (e.g. low-level lase...
Source: Drugs and Therapy Perspectives - June 30, 2023 Category: Drugs & Pharmacology Source Type: research
Manage seborrhoeic dermatitis in older adults with customised regimens that address age-related factors
AbstractAlthough seborrhoeic dermatitis can develop in people of all ages, it is especially common in older adults and severely impairs quality of life. While choosing an effective treatment regimen is important, it needs to be balanced with minimizing potential adverse effects. In addition, the treatment plan needs to be customised to address age-related factors (e.g. comorbidities, cognitive deterioration, lack of physical mobility). (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - June 27, 2023 Category: Drugs & Pharmacology Source Type: research
Mavacamten in obstructive hypertrophic cardiomyopathy: a profile of its use
AbstractMavacamten (Camzyos®), an oral, once-daily cardiac myosin inhibitor, is an important new option for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). In the USA, mavacamten is the first approved drug for the treatment of adults with symptomatic New York Heart Association (NYHA) class II –III obstructive HCM to improve functional capacity and symptoms. In a pivotal phase 3 trial in this patient population, mavacamten improved exercise capacity, symptom burden, and left ventricular outflow tract obstruction compared with placebo. Mavacamten was generally well tolerated, with...
Source: Drugs and Therapy Perspectives - June 22, 2023 Category: Drugs & Pharmacology Source Type: research
All-round approaches to increase adverse drug reaction reports: a scoping review
ConclusionThe future path in drug safety solely depends on proactive PV approaches carried out by all stakeholders, where patients play a vital role in ADR reporting. The implementation of innovative methods is essential to encourage ADR reporting. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - June 16, 2023 Category: Drugs & Pharmacology Source Type: research
First reports of adverse drug reactions
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - June 15, 2023 Category: Drugs & Pharmacology Source Type: research
